Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology

TYCHE INDUSTRIES LTD.

Healthcare › Pharmaceuticals & Biotechnology
₹104.15
at close · 9 Oct 2026
▼ 1.40 (-1.33%)

Latest filings

  1. Tyche Industries AGM: All resolutions passed, Rs 3.50 dividend declared · Board & Shareholder Meetings
  2. Tyche Industries 28th AGM approves 35 percent dividend of Rs 3.50 per share · Board & Shareholder Meetings
  3. Trading window closes Oct 1 till 48 hrs after Q2 FY26 results · Compliance
All filings ↓
Ask Nexa about TYCHE INDUSTRIES LTD.

Snapshot

What the business is, and whether it's a good one at a fair price.

A Pharmaceuticals & Biotechnology company listed on BSE, reporting revenue of ₹54 Cr over the trailing twelve months.

Market Cap
₹108 Cr
P / E (TTM)
15.8×
EV / EBITDA
8.9×
Div Yield
2.85%
Growth
-7.3%▼
Revenue 5y CAGR
PAT -19.1% · EBITDA -16.6%
Quality
12.1%▲
ROCE (5y median)
ROE 9.1% (5y median) · margin 21.4%
Leverage
0.00·
Debt / Equity · low
Net cash ₹5.61 Cr
Revenue FY21→FY26
0.7×▼
Margin −12.6 pts
₹78 Cr → ₹54 Cr
Cash conversion
0.55×▼
Operating cash ÷ profit · 5 yrs
₹30 Cr on ₹55 Cr
Moves on a normal day
1.31%·
Median daily move
Last 268 sessions · the yardstick for filing-day moves
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#32/158
P/B#13/163
ROCE#119/183
ROE#117/166
Debt / Equity#1/166
EBITDA margin#94/165
Revenue growth#44/161
Profit growth#100/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
No borrowings on the balance sheet
lower than 79% of its 166 Pharmaceuticals peers
Pays out 44% of profit as dividend
Concerns
Revenue shrinking over 5 years (−7% a year)
Profit shrinking over 5 years (−19% a year)
Erratic profits — up in only 2 of the last 5 years
Over 5 years it reported ₹55 Cr of profit and ₹30 Cr of operating cash — 0.55×
Less than 60p of every ₹1 of profit arrived as cash
Heavy working capital — 184 days of cash tied up
Customers are taking longer to pay — 80 → 133 days of receivables
FY21 → FY26

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from TYCHE INDUSTRIES LTD.'s filed financials and exchange disclosures

What does TYCHE INDUSTRIES LTD. do?

TYCHE INDUSTRIES LTD. is a Pharmaceuticals & Biotechnology company listed on BSE.

Is TYCHE INDUSTRIES LTD. profitable?

Yes. Over the trailing twelve months TYCHE INDUSTRIES LTD. reported a net profit of ₹6.93 Cr on revenue of ₹54 Cr.

Does TYCHE INDUSTRIES LTD. pay a dividend?

Yes. The dividend yield is 2.85% at the current price. It paid out 44% of its profit as dividend in FY26.

Is TYCHE INDUSTRIES LTD. debt-free?

Yes. It reported no borrowings on its 31 Mar 2026 balance sheet, and ₹5.61 Cr of cash.

Is TYCHE INDUSTRIES LTD. expensive compared with its peers?

On trailing P/E, TYCHE INDUSTRIES LTD. ranks 32 of 158 in Pharmaceuticals — cheaper than 80% of them, against an industry median of 32.0×. This is a position, not a valuation judgement.

How much does the TYCHE INDUSTRIES LTD. share price move in a day?

On a typical session TYCHE INDUSTRIES LTD. moves 1.31% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.

Where can I track TYCHE INDUSTRIES LTD.'s announcements?

Every NSE and BSE filing by TYCHE INDUSTRIES LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.